Arvinas Estrogen Receptor, Inc.
Clinical trials sponsored by Arvinas Estrogen Receptor, Inc., explained in plain language.
Biopharmaceutical company developing targeted protein degradation therapies, including for estrogen receptor-positive cancers.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New hope for Hard-to-Treat breast cancer: experimental drug ARV-471 shows promise
Disease control CompletedThis trial tests an experimental drug called ARV-471, alone or with another drug (palbociclib), in 217 people with advanced ER+/HER2- breast cancer that has stopped responding to standard treatments. The goal is to see if it is safe and can shrink tumors or slow the disease. The …
Phase: PHASE1, PHASE2 • Sponsor: Arvinas Estrogen Receptor, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for hard-to-treat breast cancer? early trial combines two targeted drugs
Disease control CompletedThis early-phase trial tested a new combination of two drugs (ARV-471 and everolimus) in 32 people with a common type of advanced breast cancer (ER+/HER2-). The main goals were to find the safest dose and check for side effects. Researchers also looked at whether the tumors shran…
Phase: PHASE1 • Sponsor: Arvinas Estrogen Receptor, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC